News
CSL: still no FTC decision on Talecris purchase
Reuters
MELBOURNE – Australian blood products and vaccines maker CSL Ltd. said on Thursday US competition regulators had yet to make a decision on its proposed $3.1 billion takeover of smaller rival Talecris Biotherapeutics.
CSL agreed to buy Talecris from its US private equity owners Cerberus Partners and Ampersand Ventures last August.
The US Federal Trade Commission has been investigating the deal and there has been speculation that it might force CSL to sell off some assets.
“This development is not unusual and provides no indication that the deal will, or will not, proceed, or the timing of an FTC decision,” CSL said.
